Browse ADRM1

Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus
Domain PF04683 Proteasome complex subunit Rpn13 ubiquitin receptor
PF16550 UCH-binding domain
Function

Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Within the complex, functions as a proteasomal ubiquitin receptor. Engages and activates 19S-associated deubiquitinases UCHL5 and PSMD14 during protein degradation. UCHL5 reversibly associate with the 19S regulatory particle whereas PSMD14 is an intrinsic subunit of the proteasome lid subcomplex.

> Gene Ontology
 
Biological Process GO:0006354 DNA-templated transcription, elongation
GO:0006368 transcription elongation from RNA polymerase II promoter
GO:0010950 positive regulation of endopeptidase activity
GO:0010952 positive regulation of peptidase activity
GO:0043248 proteasome assembly
GO:0045862 positive regulation of proteolysis
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
Molecular Function GO:0002020 protease binding
GO:0008047 enzyme activator activity
GO:0016504 peptidase activator activity
GO:0061133 endopeptidase activator activity
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
GO:0070628 proteasome binding
Cellular Component GO:0000502 proteasome complex
GO:1905368 peptidase complex
GO:1905369 endopeptidase complex
> KEGG and Reactome Pathway
 
KEGG hsa03050 Proteasome
Reactome R-HSA-5688426: Deubiquitination
R-HSA-392499: Metabolism of proteins
R-HSA-597592: Post-translational protein modification
R-HSA-5689603: UCH proteinases
R-HSA-5689880: Ub-specific processing proteases
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADRM1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADRM1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.67; FDR: 0.005 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADRM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.250.425
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1920.952
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2910.901
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2230.537
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2910.904
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1360.964
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1310.752
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.1790.915
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.530.767
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1970.927
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.010.998
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1040.101
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADRM1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADRM1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADRM1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADRM1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADRM1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADRM1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADRM1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADRM1
Nameadhesion regulating molecule 1
Aliases Rpn13; ARM-1; 110 kDa cell membrane glycoprotein; M(r) 110,000 surface antigen; proteasome regulatory partic ......
Chromosomal Location20q13.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADRM1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.